RY 174.99 0.4247% SHOP 153.96 -5.9327% TD 78.34 0.72% ENB 62.37 1.2336% BN 81.95 -0.4374% TRI 231.13 0.1603% CNQ 46.75 1.1248% CP 110.68 1.1608% CNR 150.0 0.9897% BMO 139.04 0.7901% BNS 75.56 -1.7808% CSU 4170.0 -3.4398% CM 90.35 -0.2429% MFC 44.14 -0.0679% ATD 76.17 -0.8332% NGT 55.2 2.0899% TRP 68.44 0.8398% SU 54.99 3.8527% WCN 247.53 0.4749% L 189.56 0.3122%

Fennec Pharmaceuticals Inc

Healthcare CA FRX

8.93CAD
0.26(3.00%)

Last update at 2025-01-07T15:42:00Z

Day Range

8.938.93
LowHigh

52 Week Range

5.7015.43
LowHigh

Fundamentals

  • Previous Close 8.67
  • Market Cap161.18M
  • Volume199
  • P/E Ratio58.90
  • Dividend Yield-%
  • EBITDA-13.00900M
  • Revenue TTM49.35M
  • Revenue Per Share TTM1.81
  • Gross Profit TTM 1.45M
  • Diluted EPS TTM0.10

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Minority interest - - - - -
Net income -23.86100M -17.36500M -17.83100M -12.47700M -9.01900M
Selling general administrative 17.72M 12.24M 12.95M 7.40M 5.40M
Selling and marketing expenses 2.79M - - - -
Gross profit 1.45M - 0.17M - 0.00000M
Reconciled depreciation - 0.02M 0.40M 0.06M -
Ebit -22.58900M -17.22300M -17.88500M -12.77500M -10.40900M
Ebitda -22.54300M -17.18500M -17.98500M -13.00900M -10.57600M
Depreciation and amortization 0.05M 0.04M -0.10000M - -0.16700M
Non operating income net other - - - - -
Operating income -22.58900M -17.22300M -17.88500M -13.00900M -10.40900M
Other operating expenses 24.12M 17.22M 18.05M 13.01M 10.41M
Interest expense 0.98M 0.13M 0.00000M 0.00000M 0.35M
Tax provision - - - - -
Interest income 0.20M 0.12M 0.09M 0.25M 0.52M
Net interest income -0.93200M -0.07200M -0.31500M 0.25M 0.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.15M 0.02M -0.27800M -0.29800M -0.86900M
Total revenue 1.53M 0.00000M 0.17M 0.00000M 0.00000M
Total operating expenses 24.04M 17.22M 18.05M 13.01M 10.41M
Cost of revenue 0.09M - - - 0.00000M
Total other income expense net -1.12500M -0.12300M -0.22400M 0.23M 0.52M
Discontinued operations - - - - -
Net income from continuing ops -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Net income applicable to common shares -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 26.86M 26.94M 22.41M 31.42M 14.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.04M 0.06M 0.25M 0.28M 0.23M
Total liab 38.49M 29.51M 6.64M 2.35M 2.27M
Total stockholder equity -11.62200M -2.56900M 15.77M 29.07M 11.88M
Deferred long term liab - 0.21M 0.03M - 0.26M
Other current liab 3.75M 2.22M 0.88M 0.78M 0.66M
Common stock 144.31M 142.59M 140.80M 140.73M 106.39M
Capital stock 144.31M 142.59M 140.80M 140.73M 106.39M
Retained earnings -219.24500M -203.20000M -179.48600M -162.14000M -144.03100M
Other liab - 0.26M 4.99M - -
Good will - - - - -
Other assets - 0.21M 0.03M 0.00000M 0.26M
Cash 13.27M 23.77M 21.10M 30.34M 13.65M
Cash and equivalents - 23.77M 21.10M 30.34M 13.65M
Total current liabilities 7.55M 4.61M 1.65M 2.35M 2.27M
Current deferred revenue - - - - -
Net debt 17.68M 1.12M -16.11200M -30.34400M -13.65000M
Short term debt 0.02M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total 30.95M 24.90M 4.99M - -
Other stockholder equity 62.07M 56.80M 53.21M 49.23M 48.27M
Property plant equipment - - - - -
Total current assets 26.86M 26.73M 22.39M 31.42M 13.88M
Long term investments - - - - -
Net tangible assets - -2.56900M 15.77M 29.07M 11.88M
Short term investments - - - - -
Net receivables 8.81M 1.54M - - -
Long term debt 30.93M 24.90M 5.00M - -
Inventory 2.16M 0.58M - - -
Accounts payable 3.78M 2.39M 0.78M 1.57M 1.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.24M 1.24M 1.24M 1.24M 1.24M
Additional paid in capital - - - - -
Common stock total equity - - - 140.73M 106.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00600M - 0.03M - 0.26M
Deferred long term asset charges - - - - -
Non current assets total 0.00600M 0.21M 0.03M 0.00000M 0.26M
Capital lease obligations 0.02M - - - -
Long term debt total - 25.00M 5.00M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - 0.00000M
Change to liabilities 1.61M -0.79400M -0.04100M 0.58M 0.18M
Total cashflows from investing activities - - - - 0.00000M
Net borrowings 20.17M 4.99M 4.99M 4.99M 4.99M
Total cash from financing activities 20.73M 4.98M 32.29M -0.07100M 2.35M
Change to operating activities 1.61M -0.13800M -0.62200M -0.01100M -0.04500M
Net income -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Change in cash 2.67M -9.24400M 16.69M -9.13100M -5.47900M
Begin period cash flow 21.10M 30.34M 13.65M 22.78M 28.26M
End period cash flow 23.77M 21.10M 30.34M 13.65M 22.78M
Total cash from operating activities -18.05800M -14.22200M -15.59500M -9.06000M -7.82600M
Issuance of capital stock - 0.00000M 31.97M - 0.00000M
Depreciation - 0.02M - - -
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - -
Change to inventory -0.57600M -0.57600M -0.57600M -0.57600M -
Change to account receivables -1.54500M -1.54500M -1.54500M -1.54500M -
Sale purchase of stock 0.93M 0.03M 32.29M -0.07100M 2.33M
Other cashflows from financing activities 25.73M 4.98M 0.32M -0.07100M 2.35M
Change to netincome 4.40M 4.04M 2.77M 3.08M 1.93M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.10M -0.93200M -0.76300M 0.57M 0.13M
Stock based compensation 4.09M 3.75M 2.79M 2.67M 1.82M
Other non cash items 0.47M 0.31M 0.49M 0.48M 0.10M
Free cash flow -18.05800M -14.22200M -15.59500M -9.06000M -7.82600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRX
Fennec Pharmaceuticals Inc
0.26 3.00% 8.93 58.90 212.77 3.27 57.98 2.14 15.89
MDNA
Medicenna Therapeutics Corp
-0.02 1.33% 1.48 - 204.08 - 6.92 -6.1093
EPRX
Eupraxia Pharmaceuticals Inc
0.04 0.94% 4.28 - - - 7.62 -3.8823
ONC
Oncolytics Biotech Inc
- -% 1.35 - - - 6.21 -2.4457
TH
Theratechnologies Inc.
0.18 6.19% 3.09 - 18.32 0.97 19.46 0.93 6.74

Reports Covered

Stock Research & News

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc

68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Rostislav Raykov CEO & Director 1976
Mr. Robert C. Andrade Chief Financial Officer 1975
Mr. Mark Meier Sr. VP of Commercial NA
Mr. Mark Gowland Controller NA
Mr. Lei Fang Pres of Pharstat Inc NA
Ms. Anne McKay Regulatory Consultant 1954
Mr. Alexander D. Smith M.S. Consultant NA
Mr. Terry Evans Chief Commercial Officer NA
Dr. Pierre S. Sayad M.S., Ph.D. Chief Medical Officer NA
Ms. Christiana Cioffi M.B.A. Chief Strategy Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.